Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 16th Preview)
-
Multiple myeloma regulatory milestone
Biogen won its first global approval in China for felzartamab, a monoclonal antibody for multiple myeloma. The Chinese regulator cleared the therapy for second-line use, to be used alongside lenalidomide and dexamethasone. The approval expands felzartamab’s geographic footprint and adds a new option in a crowded multiple myeloma treatment landscape, where sequencing with standard-of-care combinations often determines clinical adoption. For Biogen, the move also signals progress in translating its antibody portfolio into market access momentum beyond the US and Europe.
-
First-in-class FDA approval for a new drug class
Bristol Myers Squibb secured the first-in-class FDA nod for Zenbexus, its protein degrader in multiple myeloma. The approval positions CELMoDs (covalent and targeted protein degraders) as a successor pathway to BMS’s legacy myeloma treatments. The company is framing Zenbexus as an advance in the next generation of targeted cancer medicines, with regulatory clearance effectively validating the CELMoD mechanism in patients. BMS’s commercial strategy will hinge on how Zenbexus integrates into existing regimens and where label expansion follows the initial approval.
-
Oncology immunotherapy late-stage efficacy
Cretostimogene grenadenorepvec delivered high complete response rates in a phase III BOND-003 Cohort C study in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer with carcinoma in situ. Reported in The Lancet Oncology by Tyson et al., the single-arm trial showed complete responses in 75% of patients, exceeding a prespecified historical benchmark. Among responders, many outcomes were maintained through two years, with treatment-related adverse events reported as predominantly mild and transient. The results support a differentiated checkpoint-free, intravesical oncolytic approach in a setting where durable options remain limited after BCG failure.
-
Regulatory development disruption and milestone economics
OraSure withdrew its FDA submission for the InteliQuick CT/NG molecular test, disrupting a planned 2026 launch. In the company’s disclosure, FDA discussions led OraSure to pull the 510(k) and CLIA waiver submission after it concluded clearance would not arrive by the merger-agreement timelines with Sherlock Biosciences. As a result, OraSure expects reduced and recalculated milestone-related obligations tied to the Sherlock acquisition, with the company stating its liability for those milestone payments was reduced to zero. Operationally, the delay also shifts costs related to resubmission, but management said the net effect should be partially offset by the revised milestone structure.
-
FDA application amendment after prior complete response letter
Capricor Therapeutics said it will amend its BLA for deramiocel, seeking approval to improve limb function in Duchenne muscular dystrophy after earlier regulatory setbacks. The update follows the company’s efforts to re-focus FDA attention on primary clinical endpoints after controversy around HOPE-3 trial measures. The potential label strategy shift lifted Capricor shares materially in response to the announcement, but the regulatory pathway remains ahead. Still, the step reflects a concrete attempt to align the submission with the endpoint FDA emphasized previously for the deramiocel decision.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.